477 related articles for article (PubMed ID: 10156942)
1. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
2. A changing drug supply.
Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
[No Abstract] [Full Text] [Related]
3. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
4. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
5. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
6. Brand-name drug companies fail to meet R&D commitments.
Kondro W
CMAJ; 2006 Aug; 175(4):344. PubMed ID: 16908891
[No Abstract] [Full Text] [Related]
7. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
8. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
9. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
10. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
11. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
12. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
13. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
14. Billion-dollar market blossoms as botanicals take root.
Glaser V
Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256
[No Abstract] [Full Text] [Related]
15. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.
Enna SJ; Williams M
Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649
[No Abstract] [Full Text] [Related]
16. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
17. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
18. Market watch: upcoming market catalysts in Q2 2011.
Jeng R
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226
[No Abstract] [Full Text] [Related]
19. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
20. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
Stark Y
Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251
[No Abstract] [Full Text] [Related]
[Next] [New Search]